- Push-out Score determined
- After almost 10 years in the position
- Praise and thanks for Levine
- Suzanne Winter taking over
- Levine said 126 words
(exechange) — Sunnyvale, California, April 27, 2022 — Josh Levine, chief executive of Accuray, leaves. As announced by Accuray Inc. in a news release and in a regulatory filing published on Wednesday, April 27, 2022, Joshua H. (Josh) Levine leaves his post as chief executive officer at the specialist in radiation therapy, after almost 10 years in the role, effective June 30, 2022.
Josh Levine’s duties as CEO will be taken over by Suzanne Winter, currently President at Accuray Inc.
Josh Levine’s move coincides with a management shake-up also involving the position of Chief Financial Officer.
“Accelerate the organization’s growth and build shareholder value”
Accuray did not give an explicit reason for Josh Levine’s departure from the CEO post. Joseph E. Whitters, Chairperson of Accuray’s Board of Directors, said: “The leadership succession plan announced today is based on a thoughtful evaluation of the skills necessary to accelerate the organization’s growth and build shareholder value.”
Precise information regarding Josh Levine’s future plans was not immediately available.
Accuray said: “On April 22, 2022, Joshua H. Levine, the Company’s Chief Executive Officer, informed the Board of Directors of the Company (the “Board”) of his intention to retire as Chief Executive Officer and as member of the Board effective June 30, 2022. Suzanne Winter, President, will succeed Joshua Levine as the company’s Chief Executive Officer, effective July 1, 2022.”
Accuray further said: “Mr. Levine will retire from the Accuray Board of Directors at the end of the company’s fiscal year on June 30, 2022 and will remain available to the company in a consulting role through June 30, 2023 to ensure a smooth transition over the next year.”
“Not the result of any disagreement”
“Mr. Levine’s retirement is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices,” Accuray said.
Share price decline since April 2017
The announcement follows a decline in Accuray Inc.’s share price of 34% since April 2017.
In the position of CEO since 2012
Josh Levine became CEO of the Company in 2012.
Joshua H. Levine has served as the Company’s Chief Executive Officer since October 2012 and as the Company’s President from October 2012 to June 2021.
Levine has also served as a member of the Company’s Board since October 2012.
He has been the President, Chief Executive Officer, and a director of two other publicly traded global medical device firms, including Mentor Corporation, a surgical implant/medical device manufacturer in the aesthetics space from 2004 to 2009, and, prior to joining Accuray, with Immucor Corporation, a diagnostics manufacturer of automated instrumentation and reagents used in blood transfusion procedures.
Levine currently serves as the Non-Executive Chairman of the Board of Natus Medical Incorporated, a provider of medical devices, software and services for the newborn care, neurology, sleep, hearing and balance markets.
Levine holds a B.A. from the University of Arizona.
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding Josh Levine’s move on a scale of 0 to 10.
exechange reached out to Accuray and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 18.2022 ($).